{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:36:43Z","timestamp":1780472203230,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.berh.2019.01.011","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T11:13:50Z","timestamp":1550920430000},"page":"563-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature"],"prefix":"10.1016","volume":"32","author":[{"given":"Galia","family":"Zacay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2019.01.011_bib1","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification criteria for systemic sclerosis","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.01.011_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.berh.2010.10.007","article-title":"Epidemiology of systemic sclerosis","volume":"24","author":"Nikpour","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.01.011_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","article-title":"Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers","volume":"24","author":"Barnes","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2019.01.011_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.011_bib5","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2147\/DDDT.S99696","article-title":"Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis","volume":"10","author":"Sakkas","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.berh.2019.01.011_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","article-title":"Systemic sclerosis and localized scleroderma\u2014current concepts and novel targets for therapy","volume":"38","author":"Distler","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.berh.2019.01.011_bib7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.011_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.011_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/rheumatology\/keu435","article-title":"Treatment of systemic sclerosis with tocilizumab","volume":"54","author":"Fernandes das Neves","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.01.011_bib10","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.01.011_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/07853890.2013.771986","article-title":"Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases","volume":"45","author":"Alten","year":"2013","journal-title":"Ann Med"},{"key":"10.1016\/j.berh.2019.01.011_bib12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2019.01.011_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"2","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.011_bib14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"8","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.011_bib15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.berh.2019.01.011_bib16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"7","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.011_bib17","first-page":"151","article-title":"A\u00a0randomized, double-blind, placebo controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.01.011_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12026-014-8615-z","article-title":"Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future","volume":"61","author":"Cantarini","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.berh.2019.01.011_bib19","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/rheumatology\/keu234","article-title":"A\u00a0case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?","volume":"53","author":"Kondo","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.01.011_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/14397595.2013.874749","article-title":"Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab","volume":"25","author":"Shima","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2019.01.011_bib21","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.01.011_bib22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.01.011_bib23","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.5301\/jsrd.5000266","article-title":"Interleukin-6 and related proteins as biomarkers in systemic sclerosis","volume":"2","author":"Denton","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:17:39Z","timestamp":1761499059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1521694219300129"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.01.011","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}